Integrated Biosciences Inc., an early-stage startup that is combining synthetic biology and machine learning in the hunt for drugs that tackle cell senescence, has demonstrated its capabilities in a newly published study in Nature Aging on May 4, 2023, which employed artificial intelligence (AI) to identify three novel compounds that are highly selective for Bcl-2 and that exhibit favorable medicinal chemistry profiles.
Absci Corp. and M2gen have entered into a partnership to create new cancer medicines. Absci’s generative artificial intelligence drug creation platform will leverage M2gen’s clinical and molecular data set, ORIEN Avatar, to accelerate the creation of therapeutics for a range of malignancies and patient profiles.
Evaxion Biotech A/S has developed a new proprietary artificial intelligence (AI) platform technology, Observ, to identify a new source of targets for personalized cancer therapy, potentially enabling treatment for patients with cold tumors, normally unresponsive to immunotherapy.
Oxford Drug Design Ltd. has been engaged by Phoremost Ltd. to accelerate a targeted protein degradation discovery program that seeks to identify new E3 ligase-based therapeutic strategies to treat cancer.
Insilico Medicine Inc. has received IND clearance from China's National Medical Products Administration (NMPA) for ISM-3312, an orally available 3CLpro inhibitor for the treatment of COVID-19. ISM-3312 has a novel molecular structure and was optimized from compounds designed by Chemistry42, Insilico’s generative chemistry AI platform.
Scientists have identified proteins that changed in response to exercise specifically in trial participants whose blood sugar control improved after taking up an exercise regimen. Based on serum protein analysis, the investigators also developed a machine-learning algorithm that could predict whether an individual’s metabolic sensitivity would be improved by exercise.
Researchers have developed an algorithm that was able to create functional enzymes from scratch after being trained with the amino acid sequences of existing enzymes in the same class. Researchers from the University of California at San Francisco described their method online in Nature Biotechnology on Jan. 26, 2023. The method, which its creators have named Progen, can generate “protein sequences with a predictable function across large protein families,” according to the authors.
Perception Vision Medical Technologies Co. Ltd. (Pvmed) raised around $14 million in a series A financing round, to further develop artificial intelligence (AI) cancer treatment solutions for the two major tumor treatment methods, radiotherapy, and surgery.
Poolbeg Pharma plc has identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with Onethree Biotech Inc.
RSS
